Theresa Guilbert1, Robert S Zeiger2, Tmirah Haselkorn3, Ahmar Iqbal4, Cynthia Alvarez5, David R Mink5, Bradley E Chipps6, Stanley J Szefler7. 1. Division of Pulmonology Medicine, Cincinnati Children's Hospital & Medical Center, Cincinnati, Ohio. Electronic address: Theresa.Guilbert@cchmc.org. 2. Departments of Allergy and Research and Evaluation, Kaiser Permanente Southern California, San Diego and Pasadena, Calif. 3. EpiMetrix, Inc., Los Altos, Calif. 4. US Medical Affairs, Genentech, Inc., South San Francisco, Calif. 5. ICON, San Francisco, Calif. 6. Capital Allergy & Respiratory Disease Center, Sacramento, Calif. 7. Department of Pediatrics, Children's Hospital Colorado and University of Colorado School of Medicine, Aurora, Colo.
Abstract
BACKGROUND: There are limited data that examine differences in asthma etiology between black and white children with severe or difficult-to-treat asthma. OBJECTIVE: To describe demographic, clinical, and asthma-related outcomes in black and white children and examine whether differences in outcomes are explained by confounding factors in sequential multivariable models. METHODS: Black (n = 86) and white (n = 262) children aged 6-11 years from The Epidemiology and Natural History of Asthma: Outcomes and Treatment Regimens 3-year observational study were analyzed. Baseline demographics and clinical characteristics were described for both cohorts, and outcomes at month 12 were analyzed using statistical models, sequentially adjusting for potential confounders. RESULTS: Black children were more likely to be male (79.1% vs 66.4%; P < .05), obese (12.8% vs 1.5%; P < .001), and from a lower income stratum (USD43,400 vs 55,770; P < .001) than white children. Black children had higher geometric mean IgE levels (434.8 vs 136.8 IU/mL; P < .001), were more likely to have very poorly controlled asthma (72.1% vs 53.4%), use long-term systemic corticosteroids (30.2% vs 9.2%; P < .001), have poorer quality of life (5.5 vs 6.1; P < .001), and have an emergency department visit (27.4% vs 7.7%, P < .001) in the 3 months before month 12. Differences in asthma control and the severity of exacerbations persisted even after accounting for all confounding factors. CONCLUSIONS: Among children with severe or difficult-to-treat asthma, asthma burden is greater in black than white children particularly related to several clinical and patient-reported outcome measures that are not explained by differences in background or clinical characteristics.
BACKGROUND: There are limited data that examine differences in asthma etiology between black and white children with severe or difficult-to-treat asthma. OBJECTIVE: To describe demographic, clinical, and asthma-related outcomes in black and white children and examine whether differences in outcomes are explained by confounding factors in sequential multivariable models. METHODS: Black (n = 86) and white (n = 262) children aged 6-11 years from The Epidemiology and Natural History of Asthma: Outcomes and Treatment Regimens 3-year observational study were analyzed. Baseline demographics and clinical characteristics were described for both cohorts, and outcomes at month 12 were analyzed using statistical models, sequentially adjusting for potential confounders. RESULTS: Black children were more likely to be male (79.1% vs 66.4%; P < .05), obese (12.8% vs 1.5%; P < .001), and from a lower income stratum (USD43,400 vs 55,770; P < .001) than white children. Black children had higher geometric mean IgE levels (434.8 vs 136.8 IU/mL; P < .001), were more likely to have very poorly controlled asthma (72.1% vs 53.4%), use long-term systemic corticosteroids (30.2% vs 9.2%; P < .001), have poorer quality of life (5.5 vs 6.1; P < .001), and have an emergency department visit (27.4% vs 7.7%, P < .001) in the 3 months before month 12. Differences in asthma control and the severity of exacerbations persisted even after accounting for all confounding factors. CONCLUSIONS: Among children with severe or difficult-to-treat asthma, asthma burden is greater in black than white children particularly related to several clinical and patient-reported outcome measures that are not explained by differences in background or clinical characteristics.
Authors: Margaret A Adgent; Tebeb Gebretsadik; Cordelia R Elaiho; Ginger L Milne; Paul Moore; Terryl J Hartman; Whitney Cowell; Cecilia S Alcala; Nicole Bush; Robert Davis; Kaja Z LeWinn; Frances A Tylavsky; Rosalind J Wright; Kecia N Carroll Journal: Free Radic Biol Med Date: 2022-07-19 Impact factor: 8.101
Authors: Aubree C Honcoop; Patricia Poitevien; Ellen Kerns; Brian Alverson; Russell J McCulloh Journal: Acad Emerg Med Date: 2021-06-11 Impact factor: 5.221
Authors: Stephen Vesper; Larry Wymer; John Kroner; Jacqueline A Pongracic; Edward M Zoratti; Frédéric F Little; Robert A Wood; Carolyn M Kercsmar; Rebecca S Gruchalla; Michelle A Gill; Meyer Kattan; Stephen J Teach; Shilpa Patel; Christine C Johnson; Leonard B Bacharier; James E Gern; Daniel J Jackson; Steven M Sigelman; Alkis Togias; Andrew H Liu; William W Busse; Gurjit K Khurana Hershey Journal: J Allergy Clin Immunol Date: 2021-10-02 Impact factor: 14.290